Skip to main content
logo
Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
158.61
-1.31 (-0.82%)
Jul 31, 2026, 4:00 PM EDT - Market closed

Belite Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-77.61-36.14-31.63-12.65-9.67
Depreciation & Amortization
0.180.170.140.060.03
Stock-Based Compensation
38.928.993.821.481.53
Other Adjustments
-1.03-3.380.260.13-0.01
Change in Receivables
-0.070.06-0.06--
Changes in Accrued Expenses
3.852.461.420.370.63
Changes in Other Operating Activities
-1.23-1.39-3.79-0.860.01
Operating Cash Flow
-36.99-29.23-29.84-11.46-7.47
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.18-0.12-0.06-0.39-0.07
Sale of Property, Plant & Equipment
----0.02
Purchases of Intangible Assets
--0.04---
Purchases of Investments
-451.99-188.27---
Proceeds from Sale of Investments
147.0777.84---
Investing Cash Flow
-305.11-110.57-0.06-0.39-0.06

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
671.2183.9677.1937.990.23
Net Common Stock Issued (Repurchased)
671.2183.9677.1937.990.23
Other Financing Activities
-7.98-0.37-1.23-1.03-0.82
Financing Cash Flow
663.2383.675.9636.96-0.58

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.12-0.210.01-0.37-0.16
Net Cash Flow
321.26-56.4846.0724.75-8.27

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-37.17-29.35-29.9-11.85-7.55
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-1.11-0.96-1.12-0.59-0.79
Levered Free Cash Flow
-74.99-35.02-33.93-13.47-9.07
Unlevered Free Cash Flow
-81.58-38.87-33.97-13.64-9.2
SEC Filings: 10-K · 10-Q